Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 8
2020 2
2021 2
2022 2
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, López-Corral L, Hernani R, Ortiz-Maldonado V, Martínez-Cibrian N, Martinez AP, Maziarz RT, Williamson S, Nemecek ER, Shadman M, Cowan AJ, Green DJ, Kimble E, Hirayama AV, Maloney DG, Turtle CJ, Gauthier J. Gazeau N, et al. Among authors: voutsinas jm. Transplant Cell Ther. 2023 Jul;29(7):430-437. doi: 10.1016/j.jtct.2023.04.001. Epub 2023 Apr 7. Transplant Cell Ther. 2023. PMID: 37031746
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Hirayama AV, et al. Among authors: voutsinas jm. Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19. Blood. 2019. PMID: 30782611 Free PMC article. Clinical Trial.
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Lynch RC, Poh C, Ujjani CS, Warren EH, Smith SD, Shadman M, Morris K, Lee S, Rasmussen H, Ottemiller S, Shelby M, Keo S, Verni K, Kurtz DM, Alizadeh AA, Chabon JJ, Hogan GJ, Schulz A, Gooley T, Voutsinas JM, Gopal AK. Lynch RC, et al. Among authors: voutsinas jm. Blood Adv. 2023 Jun 13;7(11):2449-2458. doi: 10.1182/bloodadvances.2022009145. Blood Adv. 2023. PMID: 36521030 Free PMC article. Clinical Trial.
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, Wu Q, Yeung CCS, Gazeau N, Pender BS, Kirchmeier DR, Torkelson A, Chutnik AN, Cassaday RD, Chapuis AG, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Hirayama AV, et al. Among authors: voutsinas jm. Blood Adv. 2024 Jan 23;8(2):453-467. doi: 10.1182/bloodadvances.2023011287. Blood Adv. 2024. PMID: 37903325 Free PMC article. Clinical Trial.
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Graf SA, Cassaday RD, Morris K, Voutsinas JM, Wu QV, Behnia S, Lynch RC, Krakow E, Rasmussen H, Chauncey TR, Kanan S, Soma L, Smith SD, Gopal AK. Graf SA, et al. Among authors: voutsinas jm. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):176-181. doi: 10.1016/j.clml.2020.11.023. Epub 2020 Dec 3. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33358575 Free PMC article.
Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.
Samples L, Voutsinas JM MPH, Fakhri B, Khajavian S, Spurgeon SE, Stephens DM, Skarbnik AP, Mato AR, Broome C, Gopal AK, Smith SD, Lynch RC, Rainey MA, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann DA, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley TA, Ryan K, Lansigan F, Hill BT, Pongas G, Parikh SA, Roeker LE, Allan JN, Cheng R, Ujjani C, Shadman M. Samples L, et al. Among authors: voutsinas jm mph. Blood Adv. 2024 Feb 2:bloodadvances.2023011569. doi: 10.1182/bloodadvances.2023011569. Online ahead of print. Blood Adv. 2024. PMID: 38315043
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. Among authors: voutsinas jm. Cancer Med. 2022 Nov;11(22):4104-4111. doi: 10.1002/cam4.4722. Epub 2022 Mar 29. Cancer Med. 2022. PMID: 35349227 Free PMC article.
High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
Chalker C, Santana-Davila R, Voutsinas JM, Wu QV, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, Rodriguez CP. Chalker C, et al. Among authors: voutsinas jm. J Palliat Med. 2022 Apr;25(4):614-619. doi: 10.1089/jpm.2021.0323. Epub 2021 Nov 30. J Palliat Med. 2022. PMID: 34847733
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC. Chow VA, et al. Among authors: voutsinas jm. Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21. Am J Hematol. 2019. PMID: 31056762 Free PMC article. No abstract available.
17 results